KEI has filed a pre-hearing statement for the International Trade Commission, “On the United States-Mexico-Canada Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors Investigation (No.TPA-105-003)”
KEI-Pre-hearing-statement-ITC-USMCA-30Oct2018
The submission covers the following topoics:
- Patentable subject matter for medical or surgical procedures, page 2
- Exclusivity for biologics test data, including the application to certain cell and gene therapies, pages 2-4
- The USMCA provisions on injunctions, page 4
- The USMCA provisions on damages, pages 4-7
- Even more problematic for copyright, pages 7-8
- The USMCA agreement provisions on test data for biologic products, pages 8-9
- Exceptions, pages 9-12
- Copyright term, pages 12-14
- Limits on source code disclosure requirements, pages 14-15